ClinicaliQ Trial Snapshot
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus — Recruiting • Phase III • Cardiology / Cardiovascular •….
- What is being tested: Elecoglipron, a novel investigational drug, is being evaluated against oral semaglutide (an established GLP-1 receptor agonist) for efficacy, safety, and tolerability in adults with type 2 diabetes mellitus and elevated cardiovascular risk.
- Patient eligibility overview: The trial includes adults with T2DM whose blood glucose remains inadequately controlled either without treatment or despite stable background glucose-lowering therapy, with the additional requirement of increased cardiovascular risk.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Eligibility Snapshot
- : * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.